Table 3.
Unweighted and weighted association between asymptomatic vs symptom detected distant recurrences and time to death by molecular subtype risk group for women diagnosed with stage II-III breast cancer (n = 1220)
| Tumor subtype groupc | No.d | 5-year follow-up |
5-year follow-up |
Propensity weight based on receipt of surveillance systemic imaging within 3 years of diagnosisa |
Propensity weight based on how recurrences detected (asymptomatic imaging vs signs and/or symptoms)b |
|||
|---|---|---|---|---|---|---|---|---|
| 5-year follow-up |
5-year follow-up |
9-year follow-up |
5-year follow-up |
9-year follow-up |
||||
| Unweighted HR (95% CI) | Unweighted, covariatese HR (95% CI) | Weighted, no covariates HR (95% CI) | Weighted, covariatese HR (95% CI) | Weighted, covariatese HR (95% CI) | Weighted, covariatese HR (95% CI) | Weighted, covariatese HR (95% CI) | ||
| ER+ or PR+, HER2- | 610 | 1.22 (0.96 to 1.55) | 1.17 (0.89 to 1.53) | 1.21 (0.93 to 1.56) | 1.22 (0.93 to 1.60) | 1.14 (0.91 to 1.44) | 1.14 (0.87 to1.48) | 1.12 (0.90 to 1.40) |
| ER- and PR-, HER2- | 338 | 0.68 (0.51 to 0.90)f | 0.64 (0.46 to 0.89)f | 0.74 (0.55 to 0.98)f | 0.66 (0.48 to 0.91)f | 0.73 (0.54 to 0.99)f | 0.64 (0.47 to 0.88)f | 0.71 (0.53 to 0.96)f |
| HER2+ | 272 | 0.64 (0.43 to 0.94)f | 0.42 (0.25 to 0.69)f | 0.63 (0.41 to 0.98)f | 0.4 (0.24 to 0.68)f | 0.51 (0.33 to 0.80)f | 0.56 (0.36 to 0.87)f | 0.65 (0.44 to 0.95)f |
Propensity weight constructed using full cohort of 10 076 patients. Adjusting for propensity to receive surveillance systemic imaging within 3 years of diagnosis.
Propensity weight constructed using cohort of patients with distant recurrence within 5 years of diagnosis (n = 1220). Adjusting for propensity to have recurrence detected by asymptomatic systemic imaging vs signs and/or symptoms.
ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.
Number of death events per person-year in each of the tumor subtype risk groups is as follows: 5-year asymptomatic imaging detected: ER+ or PR+, HER2- = 91 of 561.99 (0.16); ER- and PR-, HER2- = 62 of 333.79 (0.19); HER2+ = 31 of 252.15 (0.12); 5-year sign and/or symptom detected: ER+ or PR+, HER2- = 274 of 1978.43 (0.14); ER- and PR-, HER2- = 219 of 830.78 (0.26), HER2+ = 144 of 816.75 (0.18); 9 years: asymptomatic imaging detected: ER+ or PR+, HER2- = 121 of 643.87 (0.19); ER- and PR-, HER2- = 75 of 333.79 (0.22); HER2+ = 46 of 301.15 (0.15); 9 years sign and/or symptom detected: ER+ or PR+, HER2- = 404 of 2333.69 (0.17); ER- and PR-, HER2- = 238 of 830.78 (0.29); HER2+ = 178 of 951.37 (0.19).
Covariates in adjusted models include the following: age, race, Hispanic ethnicity, insurance, urban or rural, zip code level median household income (quartile) and median percent with high school degree (quartile), histology, nodal status, tumor size, chemotherapy, HER2 and endocrine therapy, surgery and radiation, facility type, and Charlson comorbid conditions.
Statistically significant differences based on Wald test, P < .05.